Regeneron Pharmaceuticals (REGN) has been in the spotlight with significant fluctuations in share price noted in the market. Among main actors in these transactions are the
Murphy Pohlad Asset Management LLC, Prime Capital Investment Advisors LLC, Bronte Capital Management Pty Ltd, and AE Wealth Management LLC, all contributing to the purchase of Regeneron shares. However,
Cambiar Investors LLC and the
New York State Common Retirement Fund trimmed and sold their holdings respectively. Regeneron's 4th Quarter earnings beat expectations, with their drug
Dupixent being the contributor to this significant profit. The company's R&D is also making progress on new drugs for various diseases. They are gaining momentum with their cholesterol drug, and their clinical pipeline is growing, with
EYLEA playing a significant role in ophthalmology.
Regeneron is expected to continue delivering strong results based on these factors.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 07 Feb 2026 08:45:55 GMT -
Rating 8
- Innovation 8
- Information 8
- Rumor -6
